Last updated: September 24, 2026
Ablavar, also known as gadofosveset trisodium and previously marketed as Vasovist, is a gadolinium-based contrast agent approved by the U.S. Food and Drug Administration in 2008 for contrast-enhanced magnetic resonance angiography of the abdominal or pelvic vessels and the lower extremities. Its commercial trajectory was limited by a narrow imaging indication, competition from established gadolinium agents, hospital purchasing pressure, and the shift toward alternative MRI and vascular-imaging workflows. Ablavar is no longer an active U.S. commercial growth product, and publicly available filings do not provide a reliable standalone revenue series.
What is Ablavar and how does it work?
Ablavar is an intravenous macrocyclic? No. It is a gadolinium-based extracellular contrast agent with reversible binding to serum albumin. The active ingredient is gadofosveset trisodium.
Albumin binding increases the agent's intravascular residence time compared with conventional extracellular gadolinium contrast agents. That property was intended to improve visualization of blood vessels during magnetic resonance angiography, particularly where a longer imaging window was clinically useful.
| Attribute |
Ablavar |
| Active ingredient |
Gadofosveset trisodium |
| Product type |
Gadolinium-based MRI contrast agent |
| U.S. dosage form |
Intravenous injection |
| Strength |
0.25 mmol/mL |
| Original U.S. approval |
December 2008 |
| U.S. indication |
Contrast-enhanced MRA of abdominal or pelvic vessels and lower-extremity vessels |
| U.S. regulatory pathway |
New Drug Application |
| Main commercial rationale |
Longer intravascular imaging window through albumin binding |
| Current commercial status |
No longer an active U.S. growth product |
The FDA label identified risks associated with gadolinium exposure, including nephrogenic systemic fibrosis in patients with severe renal impairment and the potential for gadolinium retention. These risks affected the broader gadolinium-based contrast-agent class, although the commercial impact varied by product and indication. [1]
When did Ablavar lose market momentum?
Ablavar lost momentum after approval because its differentiation did not translate into broad hospital adoption.
The main commercial constraints were:
- A narrow label centered on magnetic resonance angiography rather than general MRI enhancement.
- Strong competition from lower-cost, widely adopted gadolinium agents.
- Reimbursement and hospital formulary pressure.
- Limited differentiation after imaging centers became accustomed to conventional contrast protocols.
- Reduced demand for a specialized vascular agent as imaging workflows and modality preferences changed.
Ablavar's albumin-binding mechanism created a technical advantage for vascular imaging, but the product required radiology departments to adopt a specialized agent rather than use a broadly available contrast product. That limited its addressable market.
The product also competed with noncontrast MRA, computed tomography angiography, Doppler ultrasound, and conventional extracellular gadolinium agents. These alternatives reduced the number of examinations for which Ablavar was operationally necessary.
What is the FDA status of Ablavar?
Ablavar has no meaningful current U.S. commercial trajectory based on the available public regulatory record. The product's FDA approval established the legal basis for marketing, but approval alone did not sustain commercial distribution.
The FDA's Drugs@FDA database remains the primary source for the product's original application history, labeling, and regulatory documents. The FDA label confirms the approved indication, dosage, administration requirements, and safety profile. [1]
The product should be distinguished from an actively marketed, high-revenue contrast agent. Ablavar's discontinued or inactive commercial position means that its historical approval is more relevant to regulatory precedent than to current U.S. pharmaceutical market growth.
What is the Orange Book status of Ablavar?
Ablavar's Orange Book relevance is limited. The Orange Book records approved drug applications and certain patent and exclusivity information, but it does not provide a complete record of every patent that may have supported a product's commercial position.
There is no well-established current Orange Book exclusivity position supporting an active U.S. market for Ablavar. Any historical patents associated with gadofosveset, its formulation, manufacturing process, or imaging use would need to be assessed separately from current FDA listing status.
Because Ablavar is not a current high-volume U.S. product, Orange Book-listed patent activity has not generated the visible generic-entry dispute associated with major branded medicines.
How large was the Ablavar market?
No audited, product-level revenue series for Ablavar is consistently disclosed in the public filings of its commercial rights holders. The absence of a disclosed revenue line is itself commercially relevant: Ablavar did not become a material driver of reported corporate revenue.
The product's market was constrained by the number of MRA examinations requiring a blood-pool or extended vascular imaging agent. This was materially smaller than the market for general MRI contrast agents.
Revenue trajectory
| Period |
Commercial position |
Financial interpretation |
| 2008-2010 |
Post-approval launch and market development |
Revenue investment phase; adoption depended on specialized radiology use |
| 2011-2014 |
Limited commercialization |
Product remained niche relative to broad-use MRI contrast agents |
| 2015-2017 |
Declining strategic relevance |
Competitive and reimbursement pressure reduced growth prospects |
| 2018 onward |
No meaningful U.S. growth platform |
Standalone revenue not publicly reported as material |
Ablavar's commercial economics were likely affected by the cost of maintaining manufacturing, regulatory compliance, pharmacovigilance, sales infrastructure, and distribution for a product with limited volume. Once sales failed to reach scale, fixed costs would have pressured contribution margins.
Which companies commercialized or controlled Ablavar?
Ablavar's development history involved several corporate participants. The compound was associated with EPIX Pharmaceuticals and Schering AG, with later commercial rights and product responsibility connected to Bayer and Lantheus. Corporate control and commercialization arrangements changed over time, making historical revenue attribution difficult.
The key commercial entities associated with the product include:
- EPIX Pharmaceuticals, an early developer of the technology.
- Schering AG and Bayer, associated with development and international commercialization of Vasovist.
- Lantheus Medical Imaging, associated with U.S. commercialization and the Ablavar brand.
The commercial arrangement illustrates a common contrast-agent business model: a specialized imaging product can be developed through a biotechnology platform, licensed or partnered with a large pharmaceutical company, and later transferred to a company focused on diagnostic imaging. That structure can reduce development risk but can also result in fragmented public financial reporting.
How does Ablavar compare with competing contrast agents?
Ablavar's main competitive problem was not a lack of technical differentiation. It was the limited economic value assigned to that differentiation by radiology departments and payers.
| Product category |
Primary advantage |
Competitive impact on Ablavar |
| Conventional extracellular gadolinium agents |
Broad MRI use and established protocols |
Reduced need for a specialized vascular product |
| Macrocyclic gadolinium agents |
Stability and broad clinical use |
Strengthened formulary competition |
| Noncontrast MRA |
Avoids gadolinium exposure |
Substituted for contrast-enhanced vascular imaging in selected cases |
| CT angiography |
High availability and established vascular protocols |
Competed directly for vascular imaging |
| Doppler ultrasound |
Lower cost and no gadolinium exposure |
Replaced MRI in selected peripheral vascular applications |
Ablavar's longer intravascular imaging window offered a clinical distinction, but hospitals generally evaluate contrast agents on total value, including acquisition price, workflow, reimbursement, safety monitoring, and protocol familiarity. A superior imaging characteristic does not guarantee formulary adoption when competing products are cheaper or easier to deploy.
What patents protected Ablavar?
Ablavar's intellectual-property position likely included several categories:
- Composition and chemical-structure patents covering gadofosveset or related albumin-binding gadolinium complexes.
- Formulation patents covering the injectable solution, concentration, pH, excipients, and stability.
- Method-of-use patents covering vascular magnetic resonance imaging.
- Manufacturing patents covering synthesis, purification, complexation, and quality control.
- International patent rights in Europe and other major pharmaceutical markets.
The commercial value of these rights declined as the product's market contracted. Patent protection can delay generic entry, but it cannot create demand for a narrow-use product after clinical practice shifts.
Publicly visible, high-profile Paragraph IV litigation involving Ablavar is not a major feature of the product's market history. No prominent generic challenger has become associated with a major U.S. launch dispute for Ablavar. That outcome is consistent with a product that had limited commercial scale and an uncertain return on generic development investment.
What formulation patents protected Ablavar?
Ablavar was supplied as a sterile intravenous solution containing gadofosveset trisodium. Formulation protection would have been relevant to:
- Maintaining solubility and chemical stability.
- Controlling gadolinium complex integrity.
- Preserving sterility during shelf life.
- Ensuring consistent injectable concentration.
- Managing impurities and degradation products.
Formulation rights would have been less commercially durable than broad composition rights if competitors could develop alternative formulations or rely on expired core patents. For a low-volume contrast agent, however, the practical barrier may have been manufacturing economics rather than litigation risk.
Did Ablavar face Paragraph IV challenges or generic entry?
No material U.S. Paragraph IV challenge is widely associated with Ablavar. The absence of a visible challenge does not mean that all patent rights were unassailable. It indicates that the expected generic opportunity was not sufficiently attractive to produce a major public dispute.
Generic entry would have required more than chemical equivalence. A potential entrant would need to address:
- Complex gadolinium chemistry.
- Sterile injectable manufacturing.
- Analytical characterization of the chelate.
- Stability and impurity controls.
- FDA requirements for an abbreviated or hybrid regulatory pathway.
- A small and declining market.
These factors can deter generic development even after core patent expiration. For contrast agents, manufacturing quality and supply reliability are important commercial barriers because hospitals require consistent availability and validated drug-device workflows.
What litigation and settlement agreements affected Ablavar?
Ablavar is not associated with a major public patent-litigation campaign comparable to leading oncology, diabetes, or immunology products. There is no broadly recognized settlement agreement that established a significant generic-entry date or materially altered the U.S. market.
The more important commercial event was the product's loss of strategic relevance. Discontinuation, reduced promotion, and the limited size of the vascular MRA segment had greater financial significance than patent litigation.
Is Ablavar exposed to biosimilar competition?
No. Ablavar is a chemically defined small-molecule gadolinium contrast agent, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply.
Any competitive entry would involve a generic, hybrid, or other small-molecule regulatory pathway rather than a biosimilar application. The principal barriers would be pharmaceutical equivalence, injectable manufacturing, analytical comparability, and commercial scale.
What manufacturing and intellectual-property barriers remain?
The most important barriers are technical and economic rather than regulatory exclusivity alone.
Manufacturing barriers
Gadofosveset production requires controlled chelation chemistry, removal of uncomplexed gadolinium, sterile filling, and validated quality testing. Failure to control free gadolinium or related impurities would create material safety and regulatory problems.
Intellectual-property barriers
The relevant IP risks would include:
- Patent claims covering the active complex.
- Process claims covering synthesis or purification.
- Formulation claims covering the injectable product.
- Method claims covering vascular imaging.
- Trade secrets involving scale-up and impurity control.
Patent expiration would reduce legal barriers, but it would not eliminate development cost or commercial risk.
What is the financial outlook for Ablavar?
Ablavar's financial outlook is limited. The product is best treated as a mature or discontinued niche asset rather than a platform for renewed pharmaceutical growth.
Potential value could exist in a narrow jurisdiction where:
- A supply gap persists.
- Vascular MRI use remains clinically relevant.
- Local regulatory approval can be secured at low cost.
- A distributor can operate without a large field-sales infrastructure.
- Manufacturing is available through an established contract manufacturer.
A global relaunch would face weak economics. The product would need to compete against entrenched contrast agents, noncontrast imaging, CT angiography, and hospital cost controls. The absence of a large disclosed revenue base reduces the probability that a multinational pharmaceutical company would prioritize a broad redevelopment program.
Key Takeaways
- Ablavar is gadofosveset trisodium, an albumin-binding gadolinium-based MRI contrast agent.
- The FDA approved it in 2008 for contrast-enhanced MRA of abdominal, pelvic, and lower-extremity vessels.
- Its commercial market was narrower than the market for general MRI contrast agents.
- Public filings do not establish a reliable standalone revenue history or material current revenue contribution.
- Competition came from conventional gadolinium agents, noncontrast MRA, CT angiography, and Doppler ultrasound.
- No major public Paragraph IV litigation or generic-entry settlement defines the product's market history.
- Ablavar is not exposed to biosimilar competition because it is a small-molecule contrast agent.
- Remaining barriers are primarily manufacturing complexity, sterile injectable requirements, supply economics, and limited demand.
- The product's commercial decline appears to have been driven more by market adoption and economics than by a major patent-loss event.
FAQs
Is Ablavar still available in the United States?
Ablavar is not a meaningful active U.S. commercial product. Its original FDA approval remains part of the regulatory record, but it does not have the market position of currently promoted MRI contrast agents.
What is the generic name for Ablavar?
The generic name is gadofosveset trisodium. The product was also marketed internationally under the name Vasovist.
Is Ablavar safer than conventional gadolinium contrast?
Ablavar has the safety risks associated with gadolinium-based contrast agents, including risks related to severe renal impairment and gadolinium retention. The FDA label should be used for product-specific prescribing and safety information. [1]
Could a generic company relaunch gadofosveset?
A relaunch is technically possible if regulatory, manufacturing, and commercial requirements can be satisfied. The principal obstacle is likely market size and return on investment rather than the existence of a large active patent dispute.
Did Ablavar generate material revenue for Lantheus?
Publicly available corporate disclosures do not establish Ablavar as a material standalone revenue contributor. Its commercial importance was limited compared with broader diagnostic-imaging products and other major revenue sources.
References
-
U.S. Food and Drug Administration. (2008). Ablavar (gadofosveset trisodium) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
European Medicines Agency. (n.d.). Vasovist: European public assessment report. EMA.
-
Lantheus Medical Imaging, Inc. (n.d.). Corporate filings and product information. U.S. Securities and Exchange Commission.
